References
  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2020. https://ginasthma.org.
  2. Loureiro CC, Amaral L, Ferreira JA, et al. Omalizumab for severe asthma: beyond allergic asthma. Biomed Res Int.2018;2018:3254094.
  3. Celebi Sozener Z, Aydin O, Misirligil Z, et al. Omalizumab in non-allergic asthma: a report of 13 cases. J Asthma.2018;55(7):756-763.
  4. Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM. Effectiveness of omalizumab in non-allergic severe asthma. J Biol Regul Homeost Agents. 2013;27(1):45-53.
  5. Campo Mozo P, Soto-Campos JG, Blanco Aparicio M, et al. Severe asthma phenotypes in patients controlled with omalizumab: a real-world study. Respir Med.2019; 159; 105804.
  6. de Llano LP, Vennera MdC, Álvarez FJ, et al. Effects of omalizumab in non-atopic asthma: results from a Spanish Multicenter Registry.J Asthma. 2013;50(3):296-301.
  7. Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: anti-IgE for intrinsic asthma? Thorax. 2014;69(1):94-96.
  8. Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest.2013;144(2):411-419.
  9. Pillai P, Chan YC, Wu SY, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J. 2016;48(6):1593-1601.